Mary DiBiase
Known title: Chief Operating OfficerCIK: 0001880179
Associated companies
Transaction History
| XFOR | ▲ Buy | Grant | 650,000 | $0 | 2/12/2025 | View on chart |
| XFOR | ▼ Sell | Open Market | 22,258 | $10K | 1/24/2025 | View on chart |
| XFOR | ▲ Buy | Grant | 61,178 | $0 | 1/23/2025 | View on chart |
| XFOR | ▼ Sell | Open Market | 67,695 | $38K | 10/7/2024 | View on chart |
| XFOR | ▲ Buy | Grant | 230,645 | $0 | 10/4/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 2,642 | $2K | 9/9/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 15,409 | $14K | 3/11/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 3,683 | $4K | 2/12/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 67,695 | $49K | 11/1/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 230,645 | $0 | 10/31/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 2,642 | $3K | 9/8/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 464 | $877 | 6/30/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 857 | $2K | 6/23/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 857 | $2K | 6/15/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 18,192 | $15K | 3/10/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 4,348 | $4K | 2/13/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 1,713 | — | 8/17/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 1,578 | — | 6/30/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 856 | — | 6/24/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 856 | — | 6/16/2022 | View on chart |
| XFOR | ▲ Buy | Grant | 105,000 | $0 | 3/1/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 12,545 | — | 2/11/2022 | View on chart |
| XFOR | ▲ Buy | Grant | 27,000 | $0 | 9/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.